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Purpose. To evaluate macular thickness, agreement, and intraclass repeatability in three optical coherence tomography (OCT)
devices: the time domain (TD) Stratus OCT and two spectral domain (SD) OCTs, Spectralis and Cirrus SD-OCT, in eyes with
macular edema secondary to diabetic retinopathy (DR) and retinal vein occlusion (VO). Methods. In a prospective observational
study at a university-based retina practice, retinal thickness tomography was performed simultaneously for fifty-eight patients
(91 eyes) with DR and VO employing a time domain and two spectral domain OCTs. Agreement in macular measurements was
assessed by constructing Bland-Altman plots. Intraclass repeatability was assessed by intraclass correlation coefficients (ICCs).
Results. Based on the Bland-Altman plots for central macular thickness, there was low agreement between the measurements of
Cirrus SD-OCT and Stratus OCT, Spectralis OCT and Stratus OCT, as well as Spectralis OCT and Cirrus SD-OCT among DR
and RVO patients. All three devices demonstrated high intraclass repeatability, with ICC of 98% for Stratus OCT, 97% for Cirrus
SD-OCT, and 100% for Spectralis OCT among DR patients. The ICC was 97% for Stratus OCT, 79% for Cirrus SD-OCT, and
91% for Spectralis OCT among RVO patients. Conclusion. There are low agreements among interdevice measurements. However,
intraclass repeatability is high in both TD and SD-OCT devices.
1. Introduction
Automated measurements of retinal thickness and volume
using optical coherence tomography (OCT) and imaging-
processing software are commonly used in the diagnosis and
management of retinal diseases such as diabetic retinopathy
and age-related macular degeneration [1–4]. Time domain
Stratus OCT (Carl Zeiss Meditec, Inc., Dublin, CA, USA) is
the most widely used device both in clinical and research set-
tings. Stratus OCT acquires images at a rate of 400 axial scans
per second with an axial resolution of 10 µm, and an ability
to generate measurements with high repeatability [1]. The
new generation of OCT devices employing spectral domain
technology provides an axial resolution of approximately
3 µm and improves visualization of retinal normal anatomy
as well as microstructural changes in the neurosensory
layer [5–8]. There are some differences in the intrinsic
software algorithms that each device applies to calculate
retinal thicknesses. A thickness map is calculated based on
the data collected from an array of A-scans distributed across
the macula. The number of A-scans used in Stratus OCT
is fewer and weighted more towards the center of the scan.
The method to correct for this effect, as well as different
anatomical landmarks that each device uses to specify the
outer retinal boundary, contribute to a different absolute
value for thickness measurement [1].
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There are similar differences among various spectral
domain OCTs. These differences highlight the importance
of repeatability testing for each device. The evaluation
of association among thickness measurements by different
devices is also an important issue to consider prior to
using them interchangeably in clinical and research setting.
The repeatability of macular measurements by time domain
Stratus OCT and spectral domain Cirrus SD-OCT (Carl
Zeiss Meditec, Inc.) has been tested in the context of diabetic
macular edema (DME) [1]. However, to our knowledge, the
repeatability of macular measurements obtained by Spec-
tralis HRA/OCT (Heidelberg Engineering, Inc., Heidelberg,
Germany) has not been determined in patients with different
maculopathies [9]. The goal of the index study is to evaluate
the repeatability and agreement of macular measurements by
time domain Stratus OCT versus spectral domain Spectralis
OCT and Cirrus SD-OCT in two retinal vascular diseases,
diabetic retinopathy and retinal vein occlusion.
2. Materials and Methods
Patients who had macular edema secondary to diabetic
retinopathy (DR) and retinal vein occlusion (RVO), which
was confirmed with fundus photography as well as flu-
orescein angiography, were eligible to be enrolled in the
study. The diagnosis of macular edema secondary to DR
or RVO was made by the two retina specialists (QDN and
DVD). Eyes with other conditions resulting in macular
thickening such as epiretinal membrane, vitreal macular
traction, and neovascular age-related macular degeneration
were excluded. Research design and patient deidentifica-
tion were Health Insurance Portability and Accountability
Act (HIPAA) compliant. Institutional Review Board (IRB)
approval from the Johns Hopkins Medical Institutions was
obtained.
All study subjects were scanned with each of the three
OCT machines in random order on a single visit by a single
operator. Macular thickness measurements of nine standard
subfields were analyzed. The fast macular thickness map
protocol was used to scan patients with the Stratus OCT.
Within a scan time of 1.9 seconds, the device scans six evenly
spaced 6 mm radial lines consisting of 128 A-scans per line
that intersect at the fovea (total of 768 sampled points) [1].
The 512× 128 scan pattern was applied to obtain scans with
Cirrus SD-OCT. In a scan time of 2.4 seconds, the device
scans a 6 × 6 mm area of the retina with 128 horizontal
lines, each consisting of 512 A-scans per line (total of 65,536
sampled points) [1].
The Spectralis OCT has a transverse (in tissue) resolution
of 14 microns (µm) and an axial (in tissue) resolution of
3.9 µm. With a speed of 40,000 A-scans per second, the
device scans a 6 × 6 mm area (20 × 15 degrees) of the
retina with 19 horizontal raster scans and 240 µm between
every two lines, each line consisting of 428 A-scans (total
of 8,143 sampled points). The thickness values in between
the lines are calculated using sophisticated interpolation
algorithms. The device employs its speed to rescan each
line several times and averages the data points acquired
(this is only possible with the Spectralis OCT because it is
able to track the lines and change the scan position according
to the eye movements, automatically correcting for motion
artifacts) (information obtained from the Spectralis HRA/OCT
Manual).
We obtained two high-quality scans with each device.
Scans without artifacts caused by eye movement and pap-
illary shadowing were selected as the high-quality scans on
Spectralis OCT as well as Stratus OCT and Cirrus SD-OCT.
We did not exclude any poor scans due to media opacity
and those without clear delineation of the retina layers.
Such strategy provided us data to compare scans taken by
different devices on eyes of different characteristics—those
that were and were not ideal to undergo high-quality scan.
We compared the scan results on different devices based
on the thickness of the macula. During OCT scanning, we
used an intrinsic fixation target to center the macular grid,
along with manual centering of the grid by the operator
for those images for which the grid outside fovea was not
allowed.
To calculate retinal thickness, we defined an internal and
external retinal layer position by using the intrinsic retinal
segmentation algorithms in each device. All three devices
used the protocol from the Age-Related Eye Disease Study
(AREDS) [10] to average retinal thickness within nine retinal
subfields in a 6 mm diameter circle centered on the fovea.
Retinal subfields were reported as central, inner superior,
inner nasal, inner inferior, inner temporal, outer superior,
outer nasal, outer inferior, and outer temporal. For Cirrus
SD-OCT and Spectralis OCT, when OCT device defined the
retinal segmentation algorithms on an incorrect anatomical
site, we corrected it manually and separately reported the
values after correction.
To make pair-wise comparisons of nine subfield retinal
measurements between each pair of two devices, we used the
two-tailed paired t-test with Bonferroni adjustment for mul-
tiple comparisons. By constructing Bland-Altman plots, we
assessed the agreement in macular measurements between
each device [11]. Intraclass repeatability was assessed by
intraclass correlation coefficients (ICCs) for each of the
two measurements of each patient on each of the three
devices. We calculated the coefficient of repeatability (CRW)
to assess and compare the intrasession repeatability of the
three devices. CRW is defined as 1.96∗ SW, where SW stands
for the intrasession within-subject standard deviation [1].
3. Results
Fifty-eight patients (91 eyes) were included in this study: 28
patients (61 eyes; seven patients had more than one visit,
and the eyes were scanned and considered independently at
each visit) had macular edema secondary to DR in one or
both eyes, and 30 patients (30 eyes) had macular edema from
RVO in one eye. The age range among patients with DR was
38.3 to 81.9 years (median 69.5 years) and 15 (53.6%) of
them were male. The age range among patients with RVO
was 40.6 to 87.8 years (median 68.3 years) and 20 (66.7%) of
them were male. Central retinal vein occlusion (CRVO) was
Journal of Ophthalmology 3
Table 1: Mean ± standard deviation of nine standard subfields of three OCT devices.
Diabetic macular edema Vein occlusion
Before correction After correction Before correction After correctionStratus
OCT Cirrus
SD-OCT
Spectralis
OCT
Cirrus
SD-OCT
Spectralis
OCT
Stratus
OCT Cirrus
SD-OCT
Spectralis
OCT
Cirrus
SD-OCT
Spectralis
OCT
Central 282± 99 323± 108 344± 116 323± 108 340± 108 283± 149 315± 156 359± 198 353± 241 376± 245
Inner superior 299± 65 340± 60 363± 66 339± 60 358± 67 302± 100 357± 111 389± 161 377± 162 390± 168
Inner nasal 290± 58 336± 63 357± 68 336± 62 359± 72 319± 118 348± 87 389± 139 380± 167 397± 158
Inner inferior 280± 73 325± 80 346± 83 324± 80 343± 77 307± 110 327± 61 360± 101 366± 147 378± 144
Inner temporal 295± 83 343± 74 364± 82 343± 73 351± 76 300± 117 340± 97 364± 146 363± 175 381± 178
Outer superior 251± 36 289± 44 319± 42 289± 44 317± 40 258± 76 299± 69 345± 104 311± 79 331± 83
Outer nasal 261± 57 305± 66 319± 50 304± 66 323± 68 275± 60 301± 58 336± 67 327± 86 341± 82
Outer inferior 239± 84 283± 97 295± 34 325± 80 305± 87 258± 88 272± 51 329± 109 291± 63 326± 97
Outer temporal 253± 55 290± 53 314± 61 290± 53 306± 61 242± 74 277± 44 300± 76 287± 78 298± 74
diagnosed in 13 (43.3%) of the patients and the remaining
were diagnosed with branch retinal vein occlusion (BRVO).
3.1. OCT Characteristics among DR Patients. The mean
central macular thickness was 289 µm (standard deviation
[SD]: 99 µm) on Stratus OCT device, 323 µm (SD: 108 µm)
on Cirrus SD-OCT and 344 µm (SD: 116 µm) on Spectralis
OCT. These values changed to 322 µm (SD: 108 µm) on
Cirrus SD-OCT and 340 µm (SD: 108 µm) on Spectralis
OCT after manual correction of algorithm. Table 1 presents
the mean values and SDs for nine subfields on the three
OCT devices as well as after-correction values for Cirrus
SD-OCT and Spectralis OCT devices. The mean central
macular thickness value was 21 µm (95% confidence interval
(CI): 9, 33 µm) higher on Spectralis OCT compared to
Cirrus SD-OCT and 61 µm (95% CI: 51, 72 µm) higher on
Spectralis OCT compared to Stratus OCT. The differences
decreased to 17 µm (95% CI: 5, 28 µm) between Spectralis
OCT and Cirrus SD-OCT and to 58 µm (95% CI: 45,
70 µm) between Spectralis OCT and Stratus OCT values after
manual correction of algorithms. The mean central macular
thickness was 41 µm (95% CI: 29, 53 µm) higher on Cirrus
SD-OCT compared to Stratus OCT. The difference was the
same (41 µm, 95% CI: 28, 53 µm) after manual correction
of algorithms. Table 2 shows the mean difference and 95%
CIs between retinal thickness values on the three OCT
devices for nine different subfields before and after manual
correction of algorithms. The Bland-Altman plot showed a
poor agreement for central macular thickness measurements
between each device before and after manual correction of
algorithms (Figure 1). There was an ICC of 98% (95% CI: 97,
99%) among two measurements of central thickness values
for each eye on the Stratus OCT device. ICC was reported
as 97% (95% CI: 96, 99%) on Cirrus SD-OCT and 100%
(95% CI: 99, 100%) on Spectralis OCT for central thickness
values before manual correction of algorithms and 97%
(95% CI: 96, 99%) on Cirrus SD-OCT and 99% (95% CI: 99,
100%) on Spectralis OCT for central thickness values after
correction. Table 3 shows the ICC for retinal thickness values
on the three OCT devices for nine different subfields. For
Cirrus SD-OCT and Spectralis OCT values, ICC is reported
after manual correction of algorithms as well. For central
thickness values on Stratus OCT, CRW was reported as
27 µm. CRW was 36 µm before and after manual correction
of algorithms on Cirrus SD-OCT and 5 µm before and 18 µm
after manual correction of algorithms on Spectralis OCT.
Table 4 presents CRWs for retinal thickness values on the
three OCT devices for nine different subfields. For Cirrus
SD-OCT and Spectralis OCT values, CRW is also reported
after manual correction of algorithms.
3.2. OCT Characteristics among RVO Patients. The mean
central macular thickness was 283 µm (SD: 149 µm) on the
Stratus OCT device, 315 µm (SD: 156 µm) on Cirrus SD-
OCT, and 359 µm (SD: 198 µm) on Spectralis OCT. The
value changed to 353 µm (SD: 241 µm) on Cirrus SD-OCT
and 376 µm (SD: 245 µm) on Spectralis OCT after manual
correction of algorithm (Table 1). The mean central macular
thickness value was 47 µm (95% CI: 7, 86 µm) higher on
Spectralis OCT compared to Cirrus SD-OCT, and 76 µm
(95% CI: 48, 104 µm) higher on Spectralis OCT compared
to Stratus OCT. The difference decreased to 26 µm (95% CI:
13, 38 µm) between Spectralis OCT and Cirrus SD-OCT and
93 µm (95% CI: 45, 142 µm) between Spectralis OCT and
Stratus OCT values after manual correction of algorithms.
The mean central macular thickness was 31 µm (CI: 1,
64 µm) higher on Cirrus SD-OCT compared to Stratus OCT.
The difference increased to 68 µm (95% CI: 20, 117 µm)
after manual correction of algorithms (Table 2). There was
poor agreement for central macular thickness measurements
between each device before and after manual correction of
algorithms (Figure 2). There was an ICC of 97% (95% CI: 95,
99%) among two measurements of central thickness values
for each eye on the Stratus OCT device. ICC was reported
as 79% (95% CI: 66, 93%) on Cirrus SD-OCT and 91%
(95% CI: 84, 97%) on Spectralis OCT for central thickness
values before manual correction of algorithms, and 99%
(95% CI: 99, 100%) on Cirrus SD-OCT and 100% (95% CI:
100, 100%) on Spectralis OCT for central thickness values
after correction (Table 3). For central thickness values on
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Table 4: Coefficient of repeatability (µm) for each subfield in each OCT device.
Diabetic macular edema Vein occlusion
Cirrus SD-OCT Stratus
OCT
Spectralis OCT Cirrus SD-OCT Stratus
OCT
Spectralis OCT
Before
correction
After
correction
Before
correction
After
correction
Before
correction
After
correction
Before
correction
After
correction
Central 36 36 27 5 18 146 30 54 119 7
Inner superior 52 52 33 9 8 54 30 33 18 28
Inner nasal 18 18 26 6 14 60 49 19 110 11
Inner inferior 31 30 24 8 7 30 31 37 48 24
Inner temporal 35 35 22 7 20 33 25 50 41 20
Outer superior 36 36 23 6 20 20 15 27 64 19
Outer nasal 12 11 21 4 29 16 30 34 19 8
Outer inferior 24 23 26 10 8 10 10 31 15 11
Outer temporal 34 34 40 20 39 32 19 55 9 11
Stratus OCT, CRW was reported as 54 µm. CRW was 146 µm
before and 30 µm after manual correction of algorithms on
Cirrus SD-OCT and 119 µm before and 7 µm after manual
correction of algorithms on Spectralis OCT (Table 4).
4. Discussion
Our study is one of the inaugural investigations comparing
the OCT findings in patients with macular edema from
DR and RVO between a time domain OCT, Stratus OCT,
and two spectral domain OCTs, Spectralis OCT and Cirrus
SD-OCT [1, 9]. The SD OCTs reported higher values for
macular thickness in all nine standard subfields in DR and
RVO patients compared to TD Stratus OCT. The values
obtained from the two spectral domain OCTs remained
higher after manual correction of algorithms. Spectralis
OCT detected higher macular thickness in all nine standard
subfields compared to Cirrus SD-OCT. The same difference
was detected by Forooghian et al. [1] comparing Cirrus
SD-OCT to Stratus OCT, as well as by Lammer et al. [9]
comparing Spectralis OCT, Cirrus SD-OCT, and Stratus
OCT in patients with DME.
The discrepancy among the three devices in terms of
macular thickness values reflects differences in defining reti-
nal segmentation algorithms. While Stratus OCT measures
the thickness of the retina as the distance between the inner
limiting membrane (ILM) and junction of the outer segment
(OS) and inner segment (IS) of the photoreceptors, Cirrus
SD-OCT reports it as the distance from the anterior border
of the retinal pigment epithelium (RPE) to the ILM [1], while
Spectralis OCT measures the distance from the posterior
border of the RPE to the ILM. Therefore, the macular
measurements are larger on Spectralis OCT compared to
Cirrus SD-OCT and Stratus OCT. The mean difference
between macular thickness measurements obtained by the
Cirrus SD OCT and Stratus OCT in nine different subfields
was close to 50 µm in most of the subfields, which is the
length of the outer segment of human photoreceptors [1,
12]. Bland and Altman invented the method of evaluating
agreement between measurements of two devices by plotting
their difference against their mean. The measurements can
be used interchangeably when the 95% CI of agreement
is within a clinically acceptable range [11]. Figures 1 and
2 present the Bland-Altman plots for the central subfield
values on different devices. The 95% CIs for agreement
between each two machines in DR and VO patients were
very wide. The 95% CIs remained very large after manual
correction of the algorithms. Therefore, macular thickness
measurements obtained with each of the three devices cannot
be used interchangeably with the measurements from the
other device due to poor agreement among devices [1, 9].
We evaluated the repeatability of the macular thickness
measurements of each device by performing two series of
images with each device on each patient. The ICC was
reported high for all the nine subfields on all three devices.
ICC remained high after manual correction of algorithms
for measurements by Cirrus SD-OCT and Spectralis OCT.
Although different methods were applied to measure the
repeatability of each OCT device, our results were consistent
with other reports on Stratus OCT [13, 14], as well as Cirrus
SD-OCT [1] and Spectralis OCT [9] for patients with DR.
Thus far, there have not been any published reports
on the repeatability of measurements of macular edema
in RVO. ICC was reported less than 90% on Stratus
OCT, Cirrus SD-OCT, and Spectralis OCT for some of
the segments (81–100% among DR patients and 79–100%
among those with RVO) before and after manual correction
of algorithms. The low reported ICC could be due to chance.
There is no physiological or anatomical basis to explain
the difference in macular thickness measurements in these
segments compared to the rest of the scanned area [1]. Since
the 95% CI for all these measurements is wide and greater
than 90%, the low ICC could be due to some outliers in the
measurements for ICC.
The CRW was reported as less than 40 µm for Stratus
OCT in DR patients and less than 55 µm in RVO patients.
Such index presents the half-width for the 95% CI in the
thickness measurement variation from one OCT measure-
ment to another for each patient. Our finding is similar to
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Figure 1: Bland-Altman plots of central subfield macular thickness between each device for the values before manual correction of
algorithms (a, c, and e) and after manual correction (b, d, and f) in eyes with diabetic retinopathy. Solid lines: average mean difference;
dotted lines: 95% confidence limits of agreement.
the Diabetic Retinopathy Clinical Research Network report
on Stratus OCT in DME patients [2]. The CRW ranged from
11 µm to 52 µm for Cirrus SD-OCT in DR patients before
and after manual correction of algorithms. It ranged from
10 µm to 146 µm before correction to 10 µm to 49 µm after
correction of algorithms in RVO patients. The wide range
of CRW before manual correction of algorithms reflects the
inability of the device to recognize anatomical landmarks
and define algorithms in the presence of extensive macular
edema. The CRW was large for patients with ≥800 µm in
macular thickness, for which Cirrus SD-OCT was not able to
recognize anatomical landmarks. The CRW range decreased
dramatically after manual correction of algorithms.
The CRW ranged from 4 µm to 20 µm for Spectralis SD in
DR patients before and from 7 µm to 39 µm after manual cor-
rection of algorithms. It ranged from 9 µm to 119 µm before
correction to 7 µm to 28 µm after correction of algorithms
in RVO patients. The same problem of not being able to
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Figure 2: Bland-Altman plots of central subfield macular thickness between each device for the values before manual correction of
algorithms (a, c, and e) and after manual correction (b, d, and f) in eyes with vein occlusion. Solid lines: average mean difference; dotted
lines: 95% confidence limits of agreement.
recognize anatomical landmarks and define algorithms in the
presence of extensive amount of macular edema was detected
in Spectralis OCT. The CRW range decreased dramatically
after manual correction of algorithms.
The current study provides valuable information regard-
ing the performance of different OCT devices in macular
edema from two different types of retinal vascular diseases.
To the best of our knowledge, our OCT analysis in DR
patients is one of the few reports with a large sample size
on the comparison of SD OCTs among each other as well
as with the TD OCT. Our analysis in RVO patients is the
first report of SD OCTs in patients with RVO. The index
study has evaluated the performance of OCT devices in a
real-time clinic without omission of impaired images due to
inability of the device to recognize anatomical landmarks.
Unlike other reports on this subject, we also reviewed all
images taken with SD OCTs on different types of patients and
ocular and media condition, and made manual corrections of
Journal of Ophthalmology 9
algorithms when necessary. Therefore, the index study also
presents the performance of each device in actual, clinical
situation where there are protean factors that may affect
quality of scans.
5. Conclusions
Although each OCT device has a unique method of defining
algorithms and cannot be used interchangeably, each device
has the ability to measure the retinal thickness accurately and
repeatedly. The advantage of one SD OCT over the other
or to a TD OCT might be in its ability to provide images
with more details of different retinal layers and detect small
changes in the normal anatomy of retina. Additional studies
to evaluate the quality of images by each device to define
subtle anatomical changes in different layers of retina are
necessary to make informed decision to employ which of the
available OCTs in a specific clinical setting.
Authors’ Contribution
Dr. E. Hatef, Dr. A. Khwaja, and Mr. Z. Rentiya have con-
tributed similar amount of efforts toward the conduct of the
index study and serve as cofirst authors.
Acknowledgments
Research discussed in this paper was presented in part at the
Annual Meeting of the Association for Research in Vision
and Ophthalmology (ARVO), Fort Lauderdale, FL, USA
in 2010. Dr. Q. Nguyen serves on the Scientific Advisory
Board for Heidelberg Engineering, Inc. The Johns Hopkins
University has received research support from Heidelberg
Engineering, Inc. However, Heidelberg has had no inputs in
the design, conduct, or analyses of the index study. None of
the other authors has a proprietary interest in this paper.
References
[1] F. Forooghian, C. Cukras, C. B. Meyerle, E. Y. Chew, and W.
T. Wong, “Evaluation of time domain and spectral domain
optical coherence tomography in the measurement of diabetic
macular edema,” Investigative Ophthalmology and Visual Sci-
ence, vol. 49, no. 10, pp. 4290–4296, 2008.
[2] M. G. Krzystolik, S. F. Strauber, L. P. Aiello et al., “Repro-
ducibility of macular thickness and volume using Zeiss optical
coherence tomography in patients with diabetic macular
edema,” Ophthalmology, vol. 114, no. 8, pp. 1520–1525, 2007.
[3] T. Otani, S. Kishi, and Y. Maruyama, “Patterns of diabetic
macular edema with optical coherence tomography,” Ameri-
can Journal of Ophthalmology, vol. 127, no. 6, pp. 688–693,
1999.
[4] G. J. Jaffe and J. Caprioli, “Optical coherence tomography to
detect and manage retinal disease and glaucoma,” American
Journal of Ophthalmology, vol. 137, no. 1, pp. 156–169, 2004.
[5] M. Wojtkowski, T. Bajraszewski, I. Gorczyn´ska et al., “Oph-
thalmic imaging by spectral optical coherence tomography,”
American Journal of Ophthalmology, vol. 138, no. 3, pp. 412–
419, 2004.
[6] Y. Ojima, M. Hangai, M. Sasahara et al., “Three-dimensional
imaging of the foveal photoreceptor layer in central serous
chorioretinopathy using high-speed optical coherence tomog-
raphy,” Ophthalmology, vol. 114, no. 12, pp. 2197.e1–2207.e1,
2007.
[7] W. Drexler, H. Sattmann, B. Hermann et al., “Enhanced
visualization of macular pathology with the use of ultrahigh-
resolution optical coherence tomography,” Archives of Oph-
thalmology, vol. 121, no. 5, pp. 695–706, 2003.
[8] U. Schmidt-Erfurth, R. A. Leitgeb, S. Michels et al., “Three-
dimensional ultrahigh-resolution optical coherence tomog-
raphy of macular diseases,” Investigative Ophthalmology and
Visual Science, vol. 46, no. 9, pp. 3393–3402, 2005.
[9] J. Lammer, C. Scholda, C. Pru¨nte, T. Benesch, U. Schmidt-
Erfurth, and M. Bolz, “Retinal thickness and volume measure-
ments in diabetic macular edema: a comparison of four optical
coherence tomography systems,” Retina, vol. 31, no. 1, pp. 48–
55, 2011.
[10] M. D. Davis, R. E. Gangnon, L. Y. Lee et al., “The age-related
eye disease study severity scale for age-related macular degen-
eration: AREDS report no. 17,” Archives of Ophthalmology, vol.
123, no. 11, pp. 1484–1498, 2005.
[11] J. M. Bland and D. G. Altman, “Statistical methods for assess-
ing agreement between two methods of clinical measurement,”
The Lancet, vol. 1, no. 8476, pp. 307–310, 1986.
[12] A. Hendrickson and D. Drucker, “The development of
parafoveal and mid-peripheral human retina,” Behavioural
Brain Research, vol. 49, no. 1, pp. 21–31, 1992.
[13] P. Massin, E. Vicaut, B. Haouchine, A. Erginay, M. Paques, and
A. Gaudric, “Reproducibility of retinal mapping using optical
coherence tomography,” Archives of Ophthalmology, vol. 119,
no. 8, pp. 1135–1142, 2001.
[14] A. Polito, M. Del Borrello, M. Isola, N. Zemella, and F.
Bandello, “Repeatability and reproducibility of fast macular
thickness mapping with stratus optical coherence tomogra-
phy,” Archives of Ophthalmology, vol. 123, no. 10, pp. 1330–
1337, 2005.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 201
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 201
Hindawi Publishing Corporation
http://www.hindawi.com
